The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.

Barrett's esophagus: proton pump inhibitors and chemoprevention I / G. Triadafilopoulos;A. Taddei;P. Bechi;G. Freschi;M. N. Ringressi;D. R. Degli'Innocenti;F. Castiglione;E. Masini;M. Majewski;G. Wallner;J. Sarosiek;J. F. Dillon;R. C. McCallum;K. Dvorak;A. Goldman;P. Woodland;D. Sifrim;J. E. Richter;M. Vieth;H. Neumann;C. Langner;N. Ishimura;Y. Amano;V. N. Felix. - In: ANNALS OF THE NEW YORK ACADEMY OF SCIENCES. - ISSN 1749-6632. - ELETTRONICO. - 1232:(2011), pp. 93-113. [10.1111/j.1749-6632.2011.06047.x]

Barrett's esophagus: proton pump inhibitors and chemoprevention I

TADDEI, ANTONIO;BECHI, PAOLO;FRESCHI, GIANCARLO;RINGRESSI, MARIA NOVELLA;CASTIGLIONE, FRANCESCA;MASINI, EMANUELA;
2011

Abstract

The following on proton pump inhibitors and chemoprevention in Barrett's esophagus includes commentaries on normalization of esophageal refluxate; the effects of 5-HT(4) agonists on EGF secretion and of lubripristone on chloride channels agents; the role of Campylobacter toxin production; the deleterious effects of unconjugated bile acids; the role of baclofen in nonacid reflux; the threshold for adequate esophageal acid exposure; the effects of proton pump inhibitor (PPI) therapy on normalization of esophageal pH and on cell proliferation; the role of the phenotype of cellular proliferation on the effects of PPI therapy; and the value of Symptom Index and Symptom Association Probability in the evaluation of potential response to treatment.
2011
1232
93
113
G. Triadafilopoulos;A. Taddei;P. Bechi;G. Freschi;M. N. Ringressi;D. R. Degli'Innocenti;F. Castiglione;E. Masini;M. Majewski;G. Wallner;J. ...espandi
File in questo prodotto:
File Dimensione Formato  
2011 - Barrett's esophagus proton pump inhibitors and chemoprevention I.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 634.55 kB
Formato Adobe PDF
634.55 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/580900
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact